Stem Cell and Exosome Therapy in Pulmonary Hypertension

Pulmonary hypertension is a rare and progressive illness with a devastating prognosis. Promising research efforts have advanced the understanding and recognition of the pathobiology of pulmonary hypertension. Despite remarkable achievements in terms of improving the survival rate, reducing disease p...

Full description

Saved in:
Bibliographic Details
Published in:Korean circulation journal 2022, 52(2), , pp.110-122
Main Authors: Oh, Seyeon, Jung, Ji-Hye, Ahn, Kyung-Jin, Jang, Albert Youngwoo, Byun, Kyunghee, Yang, Phillip C, Chung, Wook-Jin
Format: Article
Language:English
Subjects:
State of the Art Review
내과학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c421t-40bc675f6199fbe555001b019630c0bc949778f910e243e25fe3d354e7908fd43
cites cdi_FETCH-LOGICAL-c421t-40bc675f6199fbe555001b019630c0bc949778f910e243e25fe3d354e7908fd43
container_end_page 122
container_issue 2
container_start_page 110
container_title Korean circulation journal
container_volume 52
creator Oh, Seyeon
Jung, Ji-Hye
Ahn, Kyung-Jin
Jang, Albert Youngwoo
Byun, Kyunghee
Yang, Phillip C
Chung, Wook-Jin
description Pulmonary hypertension is a rare and progressive illness with a devastating prognosis. Promising research efforts have advanced the understanding and recognition of the pathobiology of pulmonary hypertension. Despite remarkable achievements in terms of improving the survival rate, reducing disease progression, and enhancing quality of life, pulmonary arterial hypertension (PAH) is not completely curable. Therefore, an effective treatment strategy is still needed. Recently, many studies of the underlying molecular mechanisms and technological developments have led to new approaches and paradigms for PAH treatment. Management based on stem cells and related paracrine effects, epigenetic drugs and gene therapies has yielded prospective results for PAH treatment in preclinical research. Further trials are ongoing to optimize these important insights into clinical circumstances.
doi_str_mv 10.4070/kcj.2021.0191
format article
fullrecord <record><control><sourceid>proquest_nrf_k</sourceid><recordid>TN_cdi_nrf_kci_oai_kci_go_kr_ARTI_9928414</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2626222897</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-40bc675f6199fbe555001b019630c0bc949778f910e243e25fe3d354e7908fd43</originalsourceid><addsrcrecordid>eNpVkcFPwjAUxhujEUSPXs2Oehi2Xbe2FxNCUEhINIrnZow3GWwttpuR_94OkGjf4TV5v3798j6ErgnuM8zx_Tpb9SmmpI-JJCeoS3gkwtif0-Od4g66cG6FccIYleeoE8WECsFkF_G3GqpgCGUZpHoRjL6NMxUEsyXYdLMNCh28NGVldGq3wXi7AVuDdoXRl-gsT0sHV4feQ--Po9lwHE6fnybDwTTMGCV1yPA8S3icJ0TKfA7eFsZk7q0mEc78TDLJucglwUBZBDTOIVpEMQMuscgXLOqhu72utrlaZ4UyabHrH0atrRq8ziZKSioYadmHPbtp5hUsMtC1TUu1sUXl7e9e_p_oYul1vpQQRMa8Fbg9CFjz2YCrVVW4zO8m1WAap2jii1IhuUfDPZpZ45yF_PgNwaoNxptcqTYY1Qbj-Zu_3o70bxLRD5cmiAE</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2626222897</pqid></control><display><type>article</type><title>Stem Cell and Exosome Therapy in Pulmonary Hypertension</title><source>PubMed Central Free</source><creator>Oh, Seyeon ; Jung, Ji-Hye ; Ahn, Kyung-Jin ; Jang, Albert Youngwoo ; Byun, Kyunghee ; Yang, Phillip C ; Chung, Wook-Jin</creator><creatorcontrib>Oh, Seyeon ; Jung, Ji-Hye ; Ahn, Kyung-Jin ; Jang, Albert Youngwoo ; Byun, Kyunghee ; Yang, Phillip C ; Chung, Wook-Jin</creatorcontrib><description>Pulmonary hypertension is a rare and progressive illness with a devastating prognosis. Promising research efforts have advanced the understanding and recognition of the pathobiology of pulmonary hypertension. Despite remarkable achievements in terms of improving the survival rate, reducing disease progression, and enhancing quality of life, pulmonary arterial hypertension (PAH) is not completely curable. Therefore, an effective treatment strategy is still needed. Recently, many studies of the underlying molecular mechanisms and technological developments have led to new approaches and paradigms for PAH treatment. Management based on stem cells and related paracrine effects, epigenetic drugs and gene therapies has yielded prospective results for PAH treatment in preclinical research. Further trials are ongoing to optimize these important insights into clinical circumstances.</description><identifier>ISSN: 1738-5520</identifier><identifier>EISSN: 1738-5555</identifier><identifier>DOI: 10.4070/kcj.2021.0191</identifier><identifier>PMID: 35128849</identifier><language>eng</language><publisher>Korea (South): The Korean Society of Cardiology</publisher><subject>State of the Art Review ; 내과학</subject><ispartof>Korean Circulation Journal, 2022, 52(2), , pp.110-122</ispartof><rights>Copyright © 2022. The Korean Society of Cardiology.</rights><rights>Copyright © 2022. The Korean Society of Cardiology 2022 The Korean Society of Cardiology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-40bc675f6199fbe555001b019630c0bc949778f910e243e25fe3d354e7908fd43</citedby><cites>FETCH-LOGICAL-c421t-40bc675f6199fbe555001b019630c0bc949778f910e243e25fe3d354e7908fd43</cites><orcidid>0000-0002-6286-3157 ; 0000-0002-6274-895X ; 0000-0002-9767-7098 ; 0000-0002-2422-3941 ; 0000-0001-8678-8932 ; 0000-0002-3565-7139 ; 0000-0002-8802-268X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819574/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819574/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35128849$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002809476$$DAccess content in National Research Foundation of Korea (NRF)$$Hfree_for_read</backlink></links><search><creatorcontrib>Oh, Seyeon</creatorcontrib><creatorcontrib>Jung, Ji-Hye</creatorcontrib><creatorcontrib>Ahn, Kyung-Jin</creatorcontrib><creatorcontrib>Jang, Albert Youngwoo</creatorcontrib><creatorcontrib>Byun, Kyunghee</creatorcontrib><creatorcontrib>Yang, Phillip C</creatorcontrib><creatorcontrib>Chung, Wook-Jin</creatorcontrib><title>Stem Cell and Exosome Therapy in Pulmonary Hypertension</title><title>Korean circulation journal</title><addtitle>Korean Circ J</addtitle><description>Pulmonary hypertension is a rare and progressive illness with a devastating prognosis. Promising research efforts have advanced the understanding and recognition of the pathobiology of pulmonary hypertension. Despite remarkable achievements in terms of improving the survival rate, reducing disease progression, and enhancing quality of life, pulmonary arterial hypertension (PAH) is not completely curable. Therefore, an effective treatment strategy is still needed. Recently, many studies of the underlying molecular mechanisms and technological developments have led to new approaches and paradigms for PAH treatment. Management based on stem cells and related paracrine effects, epigenetic drugs and gene therapies has yielded prospective results for PAH treatment in preclinical research. Further trials are ongoing to optimize these important insights into clinical circumstances.</description><subject>State of the Art Review</subject><subject>내과학</subject><issn>1738-5520</issn><issn>1738-5555</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpVkcFPwjAUxhujEUSPXs2Oehi2Xbe2FxNCUEhINIrnZow3GWwttpuR_94OkGjf4TV5v3798j6ErgnuM8zx_Tpb9SmmpI-JJCeoS3gkwtif0-Od4g66cG6FccIYleeoE8WECsFkF_G3GqpgCGUZpHoRjL6NMxUEsyXYdLMNCh28NGVldGq3wXi7AVuDdoXRl-gsT0sHV4feQ--Po9lwHE6fnybDwTTMGCV1yPA8S3icJ0TKfA7eFsZk7q0mEc78TDLJucglwUBZBDTOIVpEMQMuscgXLOqhu72utrlaZ4UyabHrH0atrRq8ziZKSioYadmHPbtp5hUsMtC1TUu1sUXl7e9e_p_oYul1vpQQRMa8Fbg9CFjz2YCrVVW4zO8m1WAap2jii1IhuUfDPZpZ45yF_PgNwaoNxptcqTYY1Qbj-Zu_3o70bxLRD5cmiAE</recordid><startdate>20220201</startdate><enddate>20220201</enddate><creator>Oh, Seyeon</creator><creator>Jung, Ji-Hye</creator><creator>Ahn, Kyung-Jin</creator><creator>Jang, Albert Youngwoo</creator><creator>Byun, Kyunghee</creator><creator>Yang, Phillip C</creator><creator>Chung, Wook-Jin</creator><general>The Korean Society of Cardiology</general><general>대한심장학회</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>ACYCR</scope><orcidid>https://orcid.org/0000-0002-6286-3157</orcidid><orcidid>https://orcid.org/0000-0002-6274-895X</orcidid><orcidid>https://orcid.org/0000-0002-9767-7098</orcidid><orcidid>https://orcid.org/0000-0002-2422-3941</orcidid><orcidid>https://orcid.org/0000-0001-8678-8932</orcidid><orcidid>https://orcid.org/0000-0002-3565-7139</orcidid><orcidid>https://orcid.org/0000-0002-8802-268X</orcidid></search><sort><creationdate>20220201</creationdate><title>Stem Cell and Exosome Therapy in Pulmonary Hypertension</title><author>Oh, Seyeon ; Jung, Ji-Hye ; Ahn, Kyung-Jin ; Jang, Albert Youngwoo ; Byun, Kyunghee ; Yang, Phillip C ; Chung, Wook-Jin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-40bc675f6199fbe555001b019630c0bc949778f910e243e25fe3d354e7908fd43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>State of the Art Review</topic><topic>내과학</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oh, Seyeon</creatorcontrib><creatorcontrib>Jung, Ji-Hye</creatorcontrib><creatorcontrib>Ahn, Kyung-Jin</creatorcontrib><creatorcontrib>Jang, Albert Youngwoo</creatorcontrib><creatorcontrib>Byun, Kyunghee</creatorcontrib><creatorcontrib>Yang, Phillip C</creatorcontrib><creatorcontrib>Chung, Wook-Jin</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Korean Citation Index</collection><jtitle>Korean circulation journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oh, Seyeon</au><au>Jung, Ji-Hye</au><au>Ahn, Kyung-Jin</au><au>Jang, Albert Youngwoo</au><au>Byun, Kyunghee</au><au>Yang, Phillip C</au><au>Chung, Wook-Jin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stem Cell and Exosome Therapy in Pulmonary Hypertension</atitle><jtitle>Korean circulation journal</jtitle><addtitle>Korean Circ J</addtitle><date>2022-02-01</date><risdate>2022</risdate><volume>52</volume><issue>2</issue><spage>110</spage><epage>122</epage><pages>110-122</pages><issn>1738-5520</issn><eissn>1738-5555</eissn><abstract>Pulmonary hypertension is a rare and progressive illness with a devastating prognosis. Promising research efforts have advanced the understanding and recognition of the pathobiology of pulmonary hypertension. Despite remarkable achievements in terms of improving the survival rate, reducing disease progression, and enhancing quality of life, pulmonary arterial hypertension (PAH) is not completely curable. Therefore, an effective treatment strategy is still needed. Recently, many studies of the underlying molecular mechanisms and technological developments have led to new approaches and paradigms for PAH treatment. Management based on stem cells and related paracrine effects, epigenetic drugs and gene therapies has yielded prospective results for PAH treatment in preclinical research. Further trials are ongoing to optimize these important insights into clinical circumstances.</abstract><cop>Korea (South)</cop><pub>The Korean Society of Cardiology</pub><pmid>35128849</pmid><doi>10.4070/kcj.2021.0191</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-6286-3157</orcidid><orcidid>https://orcid.org/0000-0002-6274-895X</orcidid><orcidid>https://orcid.org/0000-0002-9767-7098</orcidid><orcidid>https://orcid.org/0000-0002-2422-3941</orcidid><orcidid>https://orcid.org/0000-0001-8678-8932</orcidid><orcidid>https://orcid.org/0000-0002-3565-7139</orcidid><orcidid>https://orcid.org/0000-0002-8802-268X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1738-5520
ispartof Korean Circulation Journal, 2022, 52(2), , pp.110-122
issn 1738-5520
1738-5555
language eng
recordid cdi_nrf_kci_oai_kci_go_kr_ARTI_9928414
source PubMed Central Free
subjects State of the Art Review
내과학
title Stem Cell and Exosome Therapy in Pulmonary Hypertension
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T04%3A29%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_nrf_k&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stem%20Cell%20and%20Exosome%20Therapy%20in%20Pulmonary%20Hypertension&rft.jtitle=Korean%20circulation%20journal&rft.au=Oh,%20Seyeon&rft.date=2022-02-01&rft.volume=52&rft.issue=2&rft.spage=110&rft.epage=122&rft.pages=110-122&rft.issn=1738-5520&rft.eissn=1738-5555&rft_id=info:doi/10.4070/kcj.2021.0191&rft_dat=%3Cproquest_nrf_k%3E2626222897%3C/proquest_nrf_k%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c421t-40bc675f6199fbe555001b019630c0bc949778f910e243e25fe3d354e7908fd43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2626222897&rft_id=info:pmid/35128849&rfr_iscdi=true